DK3556866T3 - Mutationer af pik3ca-genet i humane cancere - Google Patents

Mutationer af pik3ca-genet i humane cancere Download PDF

Info

Publication number
DK3556866T3
DK3556866T3 DK19175606.3T DK19175606T DK3556866T3 DK 3556866 T3 DK3556866 T3 DK 3556866T3 DK 19175606 T DK19175606 T DK 19175606T DK 3556866 T3 DK3556866 T3 DK 3556866T3
Authority
DK
Denmark
Prior art keywords
mutations
human cancer
pik3ca gene
pik3ca
gene
Prior art date
Application number
DK19175606.3T
Other languages
English (en)
Inventor
Yardena Samuels
Victor Velculescu
Kenneth Kinzler
Bert Vogelstein
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3556866(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of DK3556866T3 publication Critical patent/DK3556866T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK19175606.3T 2004-03-02 2005-02-18 Mutationer af pik3ca-genet i humane cancere DK3556866T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54888604P 2004-03-02 2004-03-02
EP17197306.8A EP3296407B1 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers

Publications (1)

Publication Number Publication Date
DK3556866T3 true DK3556866T3 (da) 2021-05-03

Family

ID=35056655

Family Applications (3)

Application Number Title Priority Date Filing Date
DK05723277.9T DK1730303T3 (da) 2004-03-02 2005-02-18 Mutationer i pik3ca-genet ved humane cancerformer
DK19175606.3T DK3556866T3 (da) 2004-03-02 2005-02-18 Mutationer af pik3ca-genet i humane cancere
DK17197306.8T DK3296407T3 (da) 2004-03-02 2005-02-18 Mutationer i PIK3CA-genet ved humane cancerformer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05723277.9T DK1730303T3 (da) 2004-03-02 2005-02-18 Mutationer i pik3ca-genet ved humane cancerformer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK17197306.8T DK3296407T3 (da) 2004-03-02 2005-02-18 Mutationer i PIK3CA-genet ved humane cancerformer

Country Status (14)

Country Link
US (6) US8026053B2 (da)
EP (5) EP3296407B1 (da)
JP (10) JP2007530017A (da)
AU (2) AU2005227148B2 (da)
CA (1) CA2560696C (da)
CY (1) CY1121975T1 (da)
DK (3) DK1730303T3 (da)
ES (5) ES2537633T3 (da)
HU (1) HUE045690T2 (da)
LT (1) LT3296407T (da)
PL (2) PL3296407T3 (da)
PT (3) PT3296407T (da)
SI (2) SI1730303T1 (da)
WO (1) WO2005091849A2 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537633T3 (es) 2004-03-02 2015-06-10 The Johns Hopkins University Mutaciones del gen de PIK3CA en cánceres humanos
EP1849877A1 (en) * 2006-04-24 2007-10-31 Erasmus University Medical Center Rotterdam Replicative history of T-and B-cell subsets
WO2008109375A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
CN101939429A (zh) * 2007-12-03 2011-01-05 桑塔里斯制药公司 用于调节pik3ca表达的rna拮抗剂化合物
WO2009152346A2 (en) * 2008-06-11 2009-12-17 Intradigm Corporation Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
AU2011230633B2 (en) 2010-03-26 2015-01-22 Mayo Foundation For Medical Education And Research Methods and materials for detecting colorectal neoplasm
AU2011329180A1 (en) * 2010-11-15 2013-05-02 Enzon Pharmaceuticals, Inc. Methods of treating cancers with HER3 and PIK3CA antisense oligonucleotides
US20130317037A1 (en) * 2010-11-16 2013-11-28 Glaxosmithkline Intellectual Property Development Limited Method of administration and treatment
WO2012106175A1 (en) 2011-02-02 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma
AR085397A1 (es) 2011-02-23 2013-09-25 Intellikine Inc Combinacion de inhibidores de quinasa y sus usos
CN110016499B (zh) 2011-04-15 2023-11-14 约翰·霍普金斯大学 安全测序系统
KR20140050689A (ko) * 2011-07-28 2014-04-29 제넨테크, 인크. Pik3ca h1047r 녹-인 비인간 동물 유방암 모델
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
CN102816839A (zh) * 2012-07-06 2012-12-12 杭州艾迪康医学检验中心有限公司 用于检测结直肠癌pik3ca基因热点突变位点的试剂盒
CN104956225B (zh) 2012-10-29 2018-10-02 约翰·霍普金斯大学 卵巢和子宫内膜癌的帕帕尼科拉乌测试
US20140272961A1 (en) * 2013-03-13 2014-09-18 Roche Molecular Systems, Inc. Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene
CA2902916C (en) 2013-03-14 2018-08-28 Mayo Foundation For Medical Education And Research Detecting neoplasm
KR101501826B1 (ko) * 2013-04-05 2015-03-13 연세대학교 산학협력단 위암에 대한 예후 예측 모형의 제조방법
WO2015017528A1 (en) * 2013-07-30 2015-02-05 Blueprint Medicines Corporation Pik3c2g fusions
EP3126529B1 (en) 2014-03-31 2020-05-27 Mayo Foundation for Medical Education and Research Detecting colorectal neoplasm
CA2957396C (en) 2014-08-07 2021-03-09 Evrykleia LIANIDOU Method of determining pik3ca mutational status in a sample
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
CN104531854B (zh) * 2014-11-10 2017-01-18 中国人民解放军第三〇七医院 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒
US10030272B2 (en) 2015-02-27 2018-07-24 Mayo Foundation For Medical Education And Research Detecting gastrointestinal neoplasms
US10435755B2 (en) 2015-03-27 2019-10-08 Exact Sciences Development Company, Llc Detecting esophageal disorders
CN114807367A (zh) 2015-05-27 2022-07-29 奎斯特诊断投资股份有限公司 用于筛选实体瘤的组合物和方法
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
CA2992790A1 (en) 2015-08-31 2017-03-09 Mayo Foundation For Medical Education And Research Detecting gastric neoplasm
AU2016362683B2 (en) 2015-12-03 2019-11-07 Novartis Ag Treatment of cancer with a PI3K inhibitor in a patient preselected for having a PIK3CA mutation in the ctDNA
RU2608960C1 (ru) * 2016-03-18 2017-01-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "РОНЦ им. Н.Н. Блохина" Минздрава России) Клеточная линия crov Cel муцинозного рака яичников человека, предназначенная для разработки лечения таргетными препаратами
US10370726B2 (en) 2016-04-14 2019-08-06 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasia
CN109153993B (zh) 2016-04-14 2023-02-17 梅约医学教育与研究基金会 检测胰腺高度异型增生
US10934592B2 (en) 2017-02-28 2021-03-02 Mayo Foundation For Medical Education And Research Detecting prostate cancer
WO2018181863A1 (ja) * 2017-03-30 2018-10-04 国立大学法人東京大学 異なる複数の目的遺伝子の評価方法
JP7067896B2 (ja) 2017-10-27 2022-05-16 シスメックス株式会社 品質評価方法、品質評価装置、プログラム、および記録媒体
US10934594B2 (en) 2017-11-30 2021-03-02 Mayo Foundation For Medical Education And Research Detecting breast cancer
CN111363827A (zh) * 2020-04-30 2020-07-03 北京和合医学诊断技术股份有限公司 用于检测pik3ca基因突变的引物组及其应用方法
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
CN116219015A (zh) * 2023-02-06 2023-06-06 中日友好医院(中日友好临床医学研究所) 基于pcr的dna中pik3ca基因突变检测试剂盒及检测方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846624A (en) * 1996-12-06 1998-12-08 The Standard Register Company Dual face pressure sensitive label
US7670767B1 (en) * 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
US6277563B1 (en) 1997-01-16 2001-08-21 The Regents Of The University Of California Genetic alterations associated with cancer
US6558903B1 (en) 1999-06-30 2003-05-06 Millennium Pharmaceuticals, Inc. Kinases and uses thereof
ATE388226T1 (de) * 1999-08-27 2008-03-15 Novartis Vaccines & Diagnostic Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon
WO2001055321A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001294842A1 (en) * 2000-09-28 2002-04-08 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
US20020142305A1 (en) 2001-03-27 2002-10-03 Koei Chin Methods for diagnosing and monitoring ovarian cancer by screening gene copy numbers
US20030135033A1 (en) * 2002-01-04 2003-07-17 Anke Klippel-Giese Compounds and methods for the identification and/ or validation of a target
AU2003261100A1 (en) 2002-07-25 2004-02-16 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
CA2518916A1 (en) * 2003-04-03 2004-10-21 Joseph R. Garlich Pi-3 kinase inhibitor prodrugs
ES2537633T3 (es) 2004-03-02 2015-06-10 The Johns Hopkins University Mutaciones del gen de PIK3CA en cánceres humanos

Also Published As

Publication number Publication date
EP2497836A1 (en) 2012-09-12
CA2560696C (en) 2019-06-25
DK3296407T3 (da) 2019-08-19
EP2896703B1 (en) 2017-10-25
WO2005091849A3 (en) 2009-04-16
PL1730303T3 (pl) 2014-04-30
JP7169315B2 (ja) 2022-11-10
US10422006B2 (en) 2019-09-24
JP2020115891A (ja) 2020-08-06
JP6395917B2 (ja) 2018-09-26
JP2012183065A (ja) 2012-09-27
CY1121975T1 (el) 2020-10-14
JP7001735B2 (ja) 2022-02-10
ES2437590T3 (es) 2014-01-13
US20110319477A1 (en) 2011-12-29
JP6695381B2 (ja) 2020-05-20
JP2013226141A (ja) 2013-11-07
AU2005227148B2 (en) 2010-11-11
EP1730303A2 (en) 2006-12-13
JP2018153189A (ja) 2018-10-04
JP6250017B2 (ja) 2017-12-20
JP2020028300A (ja) 2020-02-27
JP5894110B2 (ja) 2016-03-23
US10704105B2 (en) 2020-07-07
US8026053B2 (en) 2011-09-27
JP2020092711A (ja) 2020-06-18
PL3296407T3 (pl) 2019-11-29
US20200024671A1 (en) 2020-01-23
EP2896703A2 (en) 2015-07-22
CA2560696A1 (en) 2005-10-06
EP3296407B1 (en) 2019-05-22
DK1730303T3 (da) 2013-11-04
PT3556866T (pt) 2021-04-30
US11549150B2 (en) 2023-01-10
US20180119231A1 (en) 2018-05-03
EP1730303B1 (en) 2013-07-31
JP2016041078A (ja) 2016-03-31
JP2007530017A (ja) 2007-11-01
PT1730303E (pt) 2013-10-31
WO2005091849A2 (en) 2005-10-06
AU2011200600A1 (en) 2011-03-10
ES2869167T8 (es) 2022-01-20
HUE045690T2 (hu) 2020-01-28
EP2497836B1 (en) 2015-01-14
EP3556866B1 (en) 2021-04-07
ES2537633T3 (es) 2015-06-10
JP7304987B2 (ja) 2023-07-07
JP5336620B2 (ja) 2013-11-06
EP1730303A4 (en) 2009-09-09
EP3296407A1 (en) 2018-03-21
US20150079593A1 (en) 2015-03-19
ES2743125T3 (es) 2020-02-18
ES2869167T3 (es) 2021-10-25
EP3556866A1 (en) 2019-10-23
US20200248275A1 (en) 2020-08-06
US20090208505A1 (en) 2009-08-20
US10787713B2 (en) 2020-09-29
AU2011200600B2 (en) 2012-02-23
ES2663248T3 (es) 2018-04-11
JP2018023400A (ja) 2018-02-15
EP2896703A3 (en) 2015-10-21
LT3296407T (lt) 2019-09-10
PT3296407T (pt) 2019-08-23
SI1730303T1 (sl) 2013-12-31
AU2005227148A1 (en) 2005-10-06
JP6694543B2 (ja) 2020-05-13
JP2022059046A (ja) 2022-04-12
SI3296407T1 (sl) 2019-09-30

Similar Documents

Publication Publication Date Title
DK3556866T3 (da) Mutationer af pik3ca-genet i humane cancere
DE502004003234D1 (de) Gegen missbrauch gesicherte darreichungsform
DE502004004205D1 (de) Gegen missbrauch gesicherte darreichungsform
DK1755671T3 (da) Terapi af platinresistent cancer
DE602005000574D1 (de) Verbinder
DE502005007353D1 (de) Zervikale zwischenwirbelprothese
NO20070297A (no) Brønnbehandling
DE602005000815D1 (de) Verbinder
DE602005021427D1 (de) Verbinder
DK1885380T3 (da) Natriummetaarsenit til anvendelse til behandling af metastatiske neoplastiske sygdomme
DE602005018315D1 (de) Rollstuhl
DE602005026361D1 (de) Make-up Zubereitung
FR2872704B1 (fr) Pluritherapie contre le cancer
DK2119472T3 (da) Hud-/hårbehandlingssystem
DE112004001618D2 (de) Pharmazeutischer Wirkstoff gegen Tumorerkrankungen
DE602005001739D1 (de) Verbinder
ATA16512004A (de) Heizgerät
IS8391A (is) Notkun á síramesíni við meðhöndlun á krabbameini
DK1773451T3 (da) Anvendelse af 7-t-butoxyiminomethylcamptothecin til behandling af uterine neoplasmer
DE502004005704D1 (de) Dispersionen
AT501087A3 (de) Medizinisches winkelstück
ATA152004A (de) Lesepult
SE0400969D0 (sv) Aryl glycine derivatives and their use
SE0402638D0 (sv) Pharmaceutical use
SE0402639D0 (sv) Pharmaceutical use